Plasma hyaluronan binding protein (PHBP) is a novel serine protease found in human plasma.
Plasma hyaluronan binding protein (PHBP) is a novel serine protease found in human plasma.
1) The amino acid sequence of PHBP is similar to that of hepatocyte growth factor activator (HGFA).
1) The domain structure of PHBP is composed of three epidermal growth factor (EGF) domains, one kringle domain and one serine protease domain from its amino-terminus. 1) This domain structure is similar to that of urinary plasminogen activator (u-PA), although u-PA has only one EGF domain. 2) Additionally, the genes of PHBP and u-PA locate closely on chromosome 10q25-q26 3) and on chromosome 10q24, 4) respectively, in humans. PHBP is present as the 70-kDa inactive single chain precursor in human plasma. It transforms to the active two chain form, 50-kDa heavy chain and 27-kDa light chain, which are linked by a disulfide bond, by autocleavage. This process is accelerated in the presence of phosphatidylethanolamine and dextran sulfate similar to factor XII (Hageman factor) of the coagulation system. Furthermore, the active heterodimer form of PHBP changes to the inactive form, 50-kDa heavy chain to two 26-kDa fragments, and 27-kDa light chain to 17-kDa and 8-kDa fragments, which are all bridged by disulfide linkages, by autocleavage. We identified the C1-inhibitor as the major inhibitor of the serine protease activity of PHBP in human plasma, but the natural substrate of PHBP has not been elucidated yet. In this paper, we describe how PHBP converts inactive single chain urinary plasminogen activator (scu-PA) to the active two chain form and cleaves a-chain and b-chain of fibrinogen in a different manner from those of thrombin and plasmin.
MATERIALS AND METHODS
Materials Thrombin, prothrombin, plasmin, plasminogen and single chain tissue plasminogen activator (sct-PA) were purchased from Sigma. Single chain urinary plasminogen activator (scu-PA) was obtained from Techno Clone, Austria. S-2444 (synthetic u-PA substrate, L-pyroglutamylglycyl-L-arginine-p-nitroaniline) was from Chromogenix, Sweden and molecular weight standards for sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) were from Gibco BRL.
Purification of PHBP PHBP was purified from human plasma with AC4 (anti-PHBP mouse monoclonal antibody)-conjugated Sepharose 4B as described previously. Briefly, human plasma (500 ml) was applied to the column of AC4-Sepharose (1 mg IgG/ml Sepharose, total volume of 50 ml).
After washings with 0.5 M NaCl, 10 mM sodium phosphate and 0.1% nonidet P-40, pH 7.4 (500 ml) and distilled water (100 ml), PHBP was eluted with 0.2 M glycine-HCl, pH 2.5 from the column. Aliquots of the purified PHBP were stored in a freezer at Ϫ80°C and were neutralized with 1 M Tris before use. SDS-PAGE SDS-PAGE was performed according to Laemmli using 10 or 12.5% polyacrylamide gel under reducing or non-reducing conditions. 5) After electrophoresis, the proteins in the gel were stained with 0.1% Coomassie brilliant blue R-250, 10% acetic acid and 30% methanol for 30 min at room temperature. The gel was destained in 10% acetic acid and 30% methanol to obtain a clear back-ground.
Purification of PHBP Substrate from Human Plasma Human plasma (500 ml) was fractionated with polyethylene glycol (PEG) 4000 to 0-5% precipitate, 5-12% precipitate, 12-23% precipitate and 23% supernatant as described previously. 6) Each precipitate was dissolved in 10 mM TrisHCl, pH 7.4 (500 ml). Each fraction (1 ml) was incubated with or without PHBP (300 ng) in 50 mM Tris-HCl and 100 mM NaCl, pH 7.4 (total volume of 15 ml) at 37°C for 1 h. The samples were analyzed on SDS-PAGE and the digested protein bands were observed after Coomassie staining. The major PHBP substrate of 60 kDa under reducing conditions was purified from the 0-5% PEG 4000 fraction with columns of diethylaminoethyl (DEAE)-Sephacel, Phenyl Toyopearl 650M, Bio Gel A-0.5 m and Hydroxyapatite. 6) Amino Acid Sequence Analysis The samples (100 pmol each) were analyzed on SDS-PAGE (10% polyacrylamide gel) under reducing conditions. After electrophoresis, the proteins in the gel were transferred to a Pro Blot membrane (Perkin Elmer Applied Biosystems) electrically. The proteins on the membrane were stained with 0.1% Coomassie brilliant blue R-250, 1% acetic acid and 40% methanol for 1 min and the membrane was destained in 50% methanol. The protein bands were cut off and the amino acid sequences were analyzed with a 473A Protein Sequencer (Perkin Elmer Applied Biosystems).
Measurement of the Activation of scu-PA by PHBP
The conversion of inactive scu-PA to active two chain u-PA (tcu-PA) by PHBP was measured according to Yoshida et al. 7) S-2444 (final concentration of 0.65 mM, synthetic u-PA substrate), scu-PA (1 mg) and each amount of PHBP were mixed in 50 mM Tris-HCl and 100 mM NaCl, pH 7.4 (final volume of 200 ml) using a 96-well microtiter plate. The plate was incubated at 37°C for the indicated time. The absorbance at 405 nm was measured with a Microplate Reader Model 450 (Bio Rad).
RESULTS

Identification of the Major PHBP Substrate in Human Plasma
The PEG fractions were digested with PHBP and analyzed on SDS-PAGE under reducing conditions (Fig. 1) . The results apparently indicated that the 60-kDa band in the 0-5% PEG fraction was the major PHBP substrate in human plasma. The minor substrate (over 200 kDa) of PHBP was also observed in the same fraction. The 60-kDa band was purified with the columns of DEAE-Sephacel, Phenyl Toyopearl 650M, Bio Gel A-0.5 m and Hydroxyapatite (data not shown). The purified protein revealed a single band (over 200 kDa) under non-reducing conditions, and 70-kDa, 60-kDa abd 50-kDa bands under reducing conditions (Fig. 2) . The amino acid sequence analyses of the 70-kDa and the 50-kDa bands indicated that they were the a-chain and the gchain of fibrinogen, respectively. We could not determine the amino acid sequence of the 60-kDa band due to the blocked amino-terminal residue. Fibrinogen is composed of two chains each of the a-chain (70 kDa), b-chain (60 kDa) and gchain (50 kDa) which are connected by disulfide bonds to form 340-kDa protein.
8) The amino-terminal amino acid of the b-chain is blocked by pyroglutamyl residue. We concluded that fibrinogen was the major substrate of PHBP in human plasma.
Characterization of the Fibrinogen Cleavage by PHBP It is known that thrombin releases amino-terminal 16 amino acids (fibrinopeptide A) from the a-chain and amino-terminal 14 amino acids (fibrinopeptide B) from the b-chain of fibrinogen to produce fibrin, which is the origin of the coagulation. 9) On the other hand, plasmin cleaves all chains of fibrinogen and fibrin at the multiple sites to cause the fibrinolysis. 10, 11) We compared the fibrinogen cleavage by PHBP with those by thrombin and plasmin (Fig. 3) . Thrombin reduced the molecular weight of fibrinogen slightly and plasmin caused the fragmentation of fibrinogen under non-reducing conditions. PHBP caused more molecular weight reduction than that of thrombin under non-reducing conditions. Thrombin digestion of fibrinogen showed cleavages of the a-chain and the b-chain but not the g-chain under reducing conditions. The fragmentations of all chains of fibrinogen were observed in the plasmin digestion under reducing conditions. In PHBP treatment, the a-chain and the b-chain disappeared and the g-chain band became dense. The amino acid sequence analysis of this dense band of the g-chain showed the amino-terminal sequence of the g-chain and the sequence from lysine 54 of the b-chain. These results suggested that PHBP cleaved the a-chain and the b-chain but not the gchain of fibrinogen, and each chain was connected by disulfide linkages to form the macromolecule (over 200 kDa). We 
. Identification of PHBP Substrates in Human Plasma
Each PEG 4000 fraction (1 ml) of human plasma was incubated with or without PHBP (300 ng) in 50 mM Tris-HCl and 100 mM NaCl, pH 7.4 (total volume of 15 ml) at 37°C for 1 h. The samples were analyzed on SDS-PAGE (10% polyacrylamide gel) under reducing conditions. After electrophoresis, the proteins in the gel were stained with Coomassie brilliant blue R-250. M: molecular weight standards, 1: 0-5% PEG ppt, 2: 1ϩPHBP, 3: 5-12% PEG ppt, 4: 3ϩPHBP, 5: 12-23% PEG ppt, 6: 5ϩPHBP, 7: 23% PEG sup and 8: 7ϩPHBP.
Fig. 2. SDS-PAGE of the Purified PHBP Substrate
The purified PHBP substrate (3 mg) was analyzed on SDS-PAGE (10% polyacrylamide gel) under non-reducing or reducing conditions. After electrophoresis, the proteins in the gel were stained with Coomassie brilliant blue R-250. M: molecular weight standards and 1: PHBP substrate. Fig. 3 . Comparison of the Digestion Patterns of Fibrinogen by Thrombin, Plasmin and PHBP Fibrinogen (3 mg) was digested with or without 300 ng each of thrombin, plasmin or PHBP in 50 mM Tris-HCl and 100 mM NaCl, pH 7.4 (total volume of 15 ml) at 37°C forinvestigated whether PHBP initiated the formation of fibrin clots in solution and whether PHBP caused fibrinolysis in zymography. 12) As we expected, both results were negative (data not shown).
Activation of scu-PA by PHBP We then examined whether PHBP cleaved (activated) prothrombin and plasminogen, and both results were negative (data not shown). However, PHBP cleaved sct-PA (data not shown), and scu-PA (50 kDa) to 30-kDa and 18-kDa fragments (Fig. 4) . It is known that inactive scu-PA is cleaved to the active two chain form (30-kDa and 18-kDa subunits).
13) Accordingly we studied whether PHBP activated scu-PA using synthetic u-PA substrate, S-24447) (Fig. 5) . Scu-PA alone and PHBP alone did not hydrolyse S-2444 efficiently. But the mixture of scu-PA and PHBP hydrolysed S-2444 effectively, indicating that PHBP converted inactive scu-PA to the active dimer form. Scu-PA was activated by PHBP in a dose-dependent manner (Fig. 6 ).
DISCUSSION
In this paper, we described that PHBP cleaved the a-chain and the b-chain, but not the g-chain, of fibrinogen and fibronectin. PHBP may act as an initial inhibitor of the coagulation which occurred at a local place in the body, because PHBP cleaved the a-chain at multiple sites, and cleaved between lysine 53 and lysine 54 of the b-chain of fibrinogen. The released fragments from the a-chain and the b-chain of fibrinogen by PHBP might have some physiological function, although the cleavage sites in the a-chain have not been determined. In fibrin formation, thrombin releases amino-terminal 16 amino acids peptide (fibrinopeptide A) which has anti-thrombin action 14) from the a-chain. It also releases amino-terminal 14 amino acids peptide (fibrinopeptide B) which increases rat blood pressure, 15) potentiates contractions of the rat uterus in response to bradykinin, 16) and serves as a weak chemoattractant for human neutrophil, 17) from the bchain of fibrinogen.
PHBP did not cleave (activate) prothrombin or plasminogen; however, it cleaved sct-PA and scu-PA. It has been reported that both sct-PA and two chain t-PA (tct-PA) have similar activities, 18) but scu-PA showed little activity while tcu-PA was more active.
13) The active tcu-PA converts inactive plasminogen to active plasmin. 19) Plasmin causes fibrinolysis, 10, 11) degrades various components of the extracellular matrix such as fibronectin, laminin, proteoglycan and collagen, 20, 21) and also activates latent matrix metaloproteases 22) and growth factors. 24) PHBP may act as the initial factor of the above pathway.
We also tried to purify the minor PHBP substrate of over 200 kDa on SDS-PAGE under reducing conditions from a 0-5% PEG fraction of human plasma. Nevertheless, we failed to isolate it because the solution gelled during the ultra-filtration, before gel-filtration. However, we could identify this protein as fibronectin by Western-blot analysis with the commercial anti-human fibronectin mouse monoclonal antibody. We may be able to detect the other more minor substrates of PHBP using more sensitive detection methods. Fig. 4 . Cleavage of scu-PA by PHBP Scu-PA (2 mg) was incubated with or without PHBP (200 ng) in 50 mM Tris-HCl and 100 mM NaCl, pH 7.4 (total volume of 15 ml) at 37°C for 1 h. The samples were analyzed on SDS-PAGE (12.5% polyacrylamide gel) under reducing conditions. After electrophoresis, the proteins in the gel were stained with Coomassie brilliant blue R-250. M: molecular weight standards, 1: scu-PA and 2: 1ϩPHBP. Fig. 5 . Activation of scu-PA by PHBP S-2444 (final concentration of 0.65 mM, synthetic u-PA substrate), scu-PA (1 mg) and PHBP (100 ng) were mixed in 50 mM Tris-HCl and 100 mM NaCl, pH 7.4 (total volume of 200 ml) using a 96-well microtiter plate. The plate was incubated at 37°C and the absorbance at 405 nm was measured at 5 min-intervals. Fig. 6 . Dose-Dependency of PHBP for the Activation of scu-PA S-2444 (final concentration of 0.65 mM), scu-PA (1 mg), and each amount of PHBP were mixed in 50 mM Tris-HCl and 100 mM NaCl, pH 7.4 (total volume of 200 ml) using a 96-well microtiter plate. The plate was incubated at 37°C for 30 min and the absorbance at 405 nm was measured.
